Name | N-[(1S)-2-[(4-fluorophenyl)methyl-methylamino]-2-oxo-1-phenylethyl]-2-[[2-(4-propan-2-yloxyphenyl)benzoyl]amino]quinoline-6-carboxamide |
---|---|
Synonyms |
unii-i6kf9af7f7
PF-02575799 |
Description | PF-02575799 is a microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 0.77±0.29 nM. |
---|---|
Related Catalog | |
Target |
IC50: 0.77±0.29 nM (MTP)[1] |
In Vitro | PF-02575799 is compound 13 from the reference[1]. |
In Vivo | PF-02575799 produces appreciable triglyceride effects at its minimally effective dose (10 mg/kg). PF-02575799 significant increase alanine transaminase at 100 mg/kg[1]. |
Animal Admin | Rats[1] Spray-dried dispersions formulated PF-02575799 is tested in a seven-day rat model. Food intake, body weight, liver TG, as well as serum alanine transaminase (ALT) are measured. In the definitive study, dose effect relationships are examined (PF-02575799 1, 3, 10, 30 and 100 mg/kg q.d.) and systemic exposures are measured[1]. |
References |
Molecular Formula | C42H37FN4O4 |
---|---|
Molecular Weight | 680.76600 |
Exact Mass | 680.28000 |
PSA | 103.86000 |
LogP | 8.02290 |